Status:
COMPLETED
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
Lead Sponsor:
Celltrion
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
Eligibility Criteria
Inclusion
- diagnosed with active ankylosing spondylitis
- BASDAI score ≥ 4 and visual analogue scale(VAS) score of spinal pain ≥ 4
Exclusion
- have total ankylosing of spine
- have allergies to infliximab
- serious infection
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
257 Patients enrolled
Trial Details
Trial ID
NCT01220518
Start Date
October 1 2010
End Date
June 1 2012
Last Update
March 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inha University Hostpital
Incheon, South Korea